Phenylpropanolamine and the hemorrhagic stroke: A new search for the culprit

Journal of Pharmacology and Pharmacotherapeutics

Volumn 3, Issue 1, 2012, Pages 4-6

  Yakoot, Mostafa ^a  

^a Green Clinic and Research Centre   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

EPHEDRINE; NON PRESCRIPTION DRUG; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE;

BRAIN HEMORRHAGE; CAUSAL ATTRIBUTION; COMMON COLD; COUGHING; DISEASE ASSOCIATION; DRUG CONTROL; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INSOMNIA; IRRITABILITY; NERVOUSNESS; NOTE; OFF LABEL DRUG USE; PATIENT SATISFACTION; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SUBARACHNOID HEMORRHAGE;

EID: 84878736867     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.92491     Document Type: Note

References (14)

1. Hoffman BB. Catecholamines, sympathomimetics, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw- Hill; 2001. p. 215-68.
2. La Grenade L. Testimony at FDA Center for Drug Evaluation and Research, Non Prescription Drugs Advisory Committee, Meeting on Safety Issues of Phenylpropanolamine (PPA) in Over-the-Counter Drug Products. October 19, 2000. Transcript available at: http://www.fda.gov/ohrms/dockets/ac/00/transcripts/ 3647t1.doc. [Last accessed on 2011 May 1].
3. Horwitz RI, Brass LM, Kernan WN, Viscoli CM. Phenylpropanolamine and Risk of Hemorrhagic Stroke, Final Report of the Hemorrhagic Stroke Project. May 10, 2000. Available at: http://www.fda.gov/ohrms/dockets/ac/00/slides/3647s1g.pdf. [Last accessed on 2011 May 1].
4. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1826-32.
5. FDA letter to manufacturers of drug products containing Phenylpropanolamine (PPA) dated 11/03/2000. Available at: http://www.fda.gov/ Drugs/DrugSafety/InformationbyDrugClass/ucm150774.htm. [Last accessed on 2011 May 1].
6. Grysiewicz RA, Thomas K, Pandey DK. Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors. Neurol Clin 2008; 26: 871-95.
7. Swendsen J, Le Moal M. Individual vulnerability to addiction. Ann N Y Acad Sci 2011; 1216: 73-85.
8. Liang W, Chikritzhs T, Lenton S. Affective disorders and anxiety disorders predict the risk of drug harmful use and dependence. Addiction. 2011. doi: 10.1111/j.1360-0443.2011.03362.x. [Epub ahead of print]
9. Büttner A. Review: The neuropathology of drug abuse. Neuropathol Appl Neurobiol 2011; 37: 118-34.
10. Ersche KD, Turton AJ, Pradhan S, Bullmore ET, Robbins TW. Drug addiction endophenotypes: impulsive versus sensation-seeking personality traits. Biol Psychiatry 2010; 68: 770-3.
11. Gorelick DA. The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv Pharmacol 1998; 42: 995-7.
12. Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D, et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 2001; 21: 522-6.
13. Broderick JP, Viscoli CM, Brott T, Kernan WN, Brass LM, Feldmann E, et al. Hemorrhagic Stroke Project Investigators. Major risk factors for aneurysmal subarachnoid hemorrhage in the young are modifiable. Stroke 2003; 34: 1375-81.
14. Feldmann E, Broderick JP, Kernan WN, Viscoli CM, Brass LM, Brott T, et al. Major risk factors for intracerebral hemorrhage in the young are modifiable. Stroke 2005; 36: 1881-5.